Intellia Therapeutics Inc (NASDAQ: NTLA) is -48.62% lower on its value in year-to-date trading and has touched a low of $5.90 and a high of $27.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NTLA stock was last observed hovering at around $12.78 in the last trading session, with the day’s gains setting it 0.82%.
Currently trading at $13.6, the stock is 16.45% and 37.86% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.11 million and changing 6.38% at the moment leaves the stock 20.57% off its SMA200. NTLA registered 16.60% gain for a year compared to 6-month loss of 20.42%. The firm has a 50-day simple moving average (SMA 50) of $9.8618 and a 200-day simple moving average (SMA200) of $11.27565.
The stock witnessed a 42.21% gain in the last 1 month and extending the period to 3 months gives it a 66.20%, and is 12.73% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.91% over the week and 7.38% over the month.
Intellia Therapeutics Inc (NTLA) has around 403 employees, a market worth around $1.41B and $45.57M in sales. Profit margin for the company is -1154.10%. Distance from 52-week low is 130.42% and -50.42% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.12%).
with sales reaching $12.26M over the same period.The EPS is expected to grow by 20.79% this year, but quarterly earnings will post -3.17% year-over-year. Quarterly sales are estimated to grow 76.22% in year-over-year returns.
Intellia Therapeutics Inc (NTLA) Top Institutional Holders
403.0 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 98.28% of the company’s shares. The shares outstanding are 103.54M, and float is at 97.42M with Short Float at 29.63%. Institutions hold 93.39% of the Float.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 11.9575% of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $214.79 million to account for 9.897 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.3839% and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 4.9497 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
The most recent transaction is an insider sale by Dulac Edward J III, the company’s EVP, Chief Financial Officer. SEC filings show that Dulac Edward J III sold 7,462 shares of the company’s common stock on Jul 23 ’25 at a price of $14.02 per share for a total of $0.1 million. Following the sale, the insider now owns 0.11 million shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Jul 01 ’25 that Clark Eliana (EVP, Chief Technical Officer) sold a total of 1,022 shares of the company’s common stock. The trade occurred on Jul 01 ’25 and was made at $9.82 per share for $10036.0. Following the transaction, the insider now directly holds 95369.0 shares of the NTLA stock.
Still, SEC filings show that on Jul 02 ’25, Dube Michael P (VP, Chief Accounting Officer) disposed off 2,503 shares at an average price of $9.95 for $24905.0. The insider now directly holds 57,137 shares of Intellia Therapeutics Inc (NTLA).
